Gilead Sciences (GILD) Other Gross PP&E Adjustments (2009 - 2026)
Gilead Sciences (GILD) reported Other Gross PP&E Adjustments of $8.4 billion for Q1 2026, up 5.76% on a YoY basis from $8.0 billion in Q1 2025, and up 334.8% quarter-over-quarter from $1.9 billion in Q4 2025.
Gilead Sciences (GILD) Other Gross PP&E Adjustments (2009 - 2026) Analysis & Trends
Gilead Sciences has reported Other Gross PP&E Adjustments for 18 years, with the latest figure at $8.4 billion in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 5.76% year-over-year to $8.4 billion; the trailing twelve-month figure through Mar 2026 stood at $8.4 billion (up 5.76% YoY), and the FY2025 full-year result was $1.9 billion, up 18.33% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at $8.4 billion, up from $1.9 billion in the prior quarter.
- The five-year high for Other Gross PP&E Adjustments was $8.4 billion in Q1 2026, with the low at -$1.8 billion in Q1 2023.
- Historically, Other Gross PP&E Adjustments has averaged $2.3 billion across 5 years, with a median of $1.0 billion in 2022.
- Annual changes were most pronounced in 2023 — Other Gross PP&E Adjustments sank 34.38% — and 2024, when it jumped 45.25%.
- Gilead Sciences' Other Gross PP&E Adjustments stood at $937.0 million in 2022, then increased by 20.28% to $1.1 billion in 2023, then jumped by 45.25% to $1.6 billion in 2024, then advanced by 18.33% to $1.9 billion in 2025, then jumped by 334.8% to $8.4 billion in 2026.
- The last three Other Gross PP&E Adjustments figures came in at $8.4 billion (Q1 2026), $1.9 billion (Q4 2025), and $8.2 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | -941.03 Mn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 49.60 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | - |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | - |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | -2.70 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 8.42 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | -1.53 Bn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.42 Bn |
| Mar 31, 2026 | 8.42 Bn |
| Dec 31, 2025 | 1.94 Bn |
| Dec 31, 2025 | 1.94 Bn |
| Sep 30, 2025 | 8.19 Bn |
| Sep 30, 2025 | 8.19 Bn |
| Jun 30, 2025 | 8.08 Bn |
| Jun 30, 2025 | 8.08 Bn |
| Mar 31, 2025 | 7.96 Bn |
| Mar 31, 2025 | 7.96 Bn |
| Dec 31, 2024 | 1.64 Bn |
| Dec 31, 2024 | 1.64 Bn |
| Dec 31, 2023 | 1.13 Bn |
| Dec 31, 2023 | 1.13 Bn |
| Sep 30, 2023 | -598.00 Mn |
| Sep 30, 2023 | -598.00 Mn |
| Jun 30, 2023 | -1.20 Bn |
| Jun 30, 2023 | -1.20 Bn |
| Mar 31, 2023 | -1.79 Bn |
| Mar 31, 2023 | -1.79 Bn |